4.65 is an obvious support zone since 13/05/2024 la (support tested a few times recently). You can predict price will move to 5.10 next? You got the crystal ball? Long term investor keep analysing and predicting future price movements. I think @Dragon328 long term investment FA skills much more practical. I love to read his posts. --------------- Posted by AngTayKor > 1 week ago | Report Abuse
@DividendGuy67 very good 👍 ------------
Im glad people realise who are the good contributors to watch out for and be thankful for their posts.
Posted by Michaelchan2024 > 1 hour ago | Report Abuse @ATK, you mentioned you don't hold any Genting shares. However, what puzzles me is why you are here on the Genting forum? -----------
Still observing price action and reaction so my trading skill not rusty + how the crowd is thinking for this stock. To become a better boyfriend, you need to understand your girlfriend very well. To trade a stock well, you need to understand the behaviour of the stock well. I still manage to nail the important top (5.20 zone) and bottom (4.45 zone) for this stock during 2024. Call this a trader's life long learning process, Im forever a student of the stock market. I treat this business very seriously. I trade to win money.
No money now, all showhand into Taurx, which I believe can give me much higher returns than stock trading. But some day I will take back all my Taurx investment capital and start stock trading business again.
Posted by Pinky > 2 hours ago | Report Abuse A stock market investor/trader who only trades Genting and nothing else, based on his activity in i3. Only lunar month ghost will believe he's not here with an agenda. Period. ----------
@Pinky I have previously answered this question many times already.
Posted by AngTayKor > 2024-03-11 16:18 | Report Abuse New data presentation on 7/3 at local time 8.50am. Not regulatory approvals yet. Reminder: Regulatory approvals not so soon yet. Still got hurdles to cross especially the corrupted FDA. ------------- Posted by AngTayKor > 2024-03-11 18:36 | Report Abuse Please remember history lesson becareful of 5.20 zone LKT waiting to dump. Price action of afternoon session dont look good. -------------- Posted by Michael_chan2022 > 2024-03-12 11:34 | Report Abuse Be careful. Another short squeeze in the afternoon ----------- Posted by AngTayKor > 2024-03-12 11:46 | Report Abuse Unlikely ------------ Posted by keyman > 2024-03-12 12:19 | Report Abuse Sifu @Balian @micheal @ATK@neoths All say downward is unlikely. How am I catch the boat now? Sold 4.85 then buy back 4.97 loss 10 cents leh... ------------ Posted by AngTayKor > 2024-03-12 14:09 | Report Abuse Read clearly. I said whales exited yesterday
----------- Posted by Michael_chan2022 > 2024-03-12 12:11 | Report Abuse
ATK a ghost or not you decide lor. Hope some traders / trader cum investors here have read and exited promptly near the 5.20 top.
Then buy again at around 4.50 zone, exit at around 4.8+ zone. Then buy again at around 4.50 zone, exit at around 4.8+ zone. Then buy again at around 4.20 zone, exit at around 4.50 zone.
Its not difficult to trade this stock. I started buying when price was 2.97. When I stopped trading this stock long time ago, i think its equivalent to profit of selling the stock at over 8.00.
Just came back from a routine morning walk in the garden, see a lots of same guys still stick in this forum . well I guess price will not go far at the moment.
Continue Makan!! Anticipating next week quarterly report, back to back RM 500m net profit and RM 7 billion revenue and hopefully 30% increase in dividends payout.
looking at Q1 profit and current price, genB is trading at PER of 7.3x only..... so undemanding, and if it can issue higher than 6c div (can double to 12c if u ask me :-) as compared to last quarter div) which is surely expected..... there is only upside here on :-) happy hunting....
Samsung Electronics' main union in South Korea is set to strike over pay starting Thursday. This is an all out protest with no signs of the COVID pandemic holding them back.. Another area of expertise in fear mongering? 😀
@Balian ..... ur extremely pessimistic on the covid front, I dont see any of these news on the main portals, and evenly more extreme on the pump and dump strategy..... so ur cup is half empty rather than half full :-)
Dont worry Im sure a lot of people dont bother to read your posts or take them seriously anyway. Its social media after all kena conned here quite common la.
Posted by Michaelchan2024 > 27 minutes ago | Report Abuse Ho ho ho... my GenM did well today too. Strong closing! 😄 -----------
Good to see investors hedging their bets between mother n sons. The mother seems to be unable to get all her sons to behave well all at once. Q1 Singapore son behaved well but Malaysia son misbehaved. Q2 the Singapore son not behaving as expected but i think Malaysia son shd be good. Adopted son Christmas season report card will be out.
@Choysun, not that im biased sexism but because all descendants still bearing the Genting / RW surname even after having their own family, kids, grandkids etc. 😀
Public investment has raised the target price of Genting Bhd to RM 6.
Last quarter actually did amazingly. Genting only need emulate and match last quarter results, NAP would surpassed RM 9.
Dividend should be higher compares to previous years. Having said that, given genm is propionately higher in percentage. It is better to hold genm if you are aiming for dividends.
Overall, Genting EPS should increase, this should resulting higher share price.
Lilly’s anti-tau pill for Alzheimer’s fails in Phase 2 study
One month after the long-awaited approval of its first Alzheimer’s drug, Eli Lilly said that another experimental medicine aimed at slowing dementia failed in a Phase 2 study of 330 people.
The drug, known as an OGA inhibitor, was designed to prevent a protein called tau from clumping in the brain. Tau often builds up after amyloid plaques — the target of Lilly’s recently approved Kisunla — have formed. Tau proteins are believed to play a bigger role in the death of brain cells.
In the company’s earnings call with investors on Thursday morning, chief scientific officer Dan Skovronsky said that both low and high doses of the drug “failed to meet the primary endpoint” on Lilly’s own scale measuring cognitive decline. Lilly plans to present detailed results at the Clinical Trials on Alzheimer’s Disease conference, which begins in late October.
But Skovronksy emphasized that Lilly isn’t giving up on developing new tau-targeting drugs altogether. “While this negative outcome was disappointing, we remain committed to tau as a high conviction target in Alzheimer’s disease and plan to continue studying tau biology,” he said.
nies working on their own OGA inhibitors. Biogen is testing its own pill in a Phase 1 study. And the Swiss biotech Asceneuron last month raised $100 million to test an OGA inhibitor in a Phase 2 study.
In the run-up to the approval of Kisunla, the Indianapolis drugmaker has increasingly discussed a future where amyloid-busting and tau-lowering drugs are paired together for greater effect. Its OGA inhibitor was especially exciting, because as a pill, it could be a more accessible alternative to Kisunla, which requires monthly infusions and repeated brain scans to monitor for side effects.
The pill inhibits an enzyme called O-GlcNAcase, or OGA, that chemically alters tau proteins and makes them more prone to form toxic tangles that kill brain cells. In an interview with Endpoints News last month, Mark Mintun, Lilly’s VP of neuroscience research and development, downplayed the molecule’s chances of success.
"The OGA inhibitor does a really remarkable job in the animals. But it does it in a very indirect way,” he said. “If we designed something that attacked the tau itself or attacked the tau tangles themselves, we might feel really confident that this is going to work in humans.”
“We joke that we’ve cured Alzheimer’s in mice a lot of times,” Mintun added. “A lot of things just don’t translate to the human Alzheimer’s condition. And we will not be surprised if this is one of those things that doesn’t translate. We feel like we have to try it.”
Lilly has previously tried targeting tau directly with an antibody drug, which failed. Mintun said the company is working on another small molecule that targets tau directly inside brain cells, and a genetic medicine that uses an siRNA to prevent brain cells from making tau in the first place.
In an interview with Endpoints last August, Skovronksy compared tau drugs to the decades-long efforts to attack amyloid in many different ways. “It’s a bit like amyloid,” he said. “We have such conviction on the target, we’re willing to attack it from different mechanisms until we find the mechanism that can actually affect the target. I know that feels stubborn, but to us it just feels logical.”
Research on Taofu in the AD field is getting very fashionable now. Mab drugs are giving so little symptomatic returns with so high risk including deaths and permanent severe brain injuries, at a very high cost + lack of medical infrastructure and trained personnel to roll out Mab drugs.
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
RInvest
49 posts
Posted by RInvest > 2024-08-15 10:30 | Report Abuse
In between price … potong stim